Replies to post #30271 on Biotech Values

[gofishmarko]

Re: Handicapping VX-950 (new survey):

Dew,

I've already voted so it's too late for me , but after rereading your post on the survey , I can still see a possible source of confusion. You said :

"... let’s make the simplification that our handicapping pertains to the 420 patients in these two trials who receive VX-950. (I think this is the way Josh Boger intended his SVR comments on the GS webcast to be interpreted.)"

Surely what you want us to pick is the expected result for the BEST VX-950 arm(s), not the overall response obtained from all 420 VX-950 patients , since the best data will guide P3 development.